WO2013027694A1 - Sondes pour l'imagerie moléculaire permettant de diagnostiquer une maladie de conformation - Google Patents
Sondes pour l'imagerie moléculaire permettant de diagnostiquer une maladie de conformation Download PDFInfo
- Publication number
- WO2013027694A1 WO2013027694A1 PCT/JP2012/070978 JP2012070978W WO2013027694A1 WO 2013027694 A1 WO2013027694 A1 WO 2013027694A1 JP 2012070978 W JP2012070978 W JP 2012070978W WO 2013027694 A1 WO2013027694 A1 WO 2013027694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- mmol
- atom
- general formula
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 15
- 201000010099 disease Diseases 0.000 title claims description 14
- 238000003384 imaging method Methods 0.000 title description 14
- 239000000523 sample Substances 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 124
- -1 dicyanovinyl group Chemical group 0.000 claims abstract description 48
- 125000006575 electron-withdrawing group Chemical group 0.000 claims abstract description 17
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 11
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 5
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 56
- 230000002285 radioactive effect Effects 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 239000013522 chelant Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 229910003827 NRaRb Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052705 radium Inorganic materials 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 44
- 230000027455 binding Effects 0.000 abstract description 13
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 3
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 3
- 150000001491 aromatic compounds Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 46
- 238000003786 synthesis reaction Methods 0.000 description 46
- 239000000243 solution Substances 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 39
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- 239000002904 solvent Substances 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 208000024827 Alzheimer disease Diseases 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 239000007850 fluorescent dye Substances 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 17
- 239000011734 sodium Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000004237 preparative chromatography Methods 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 9
- 229940125758 compound 15 Drugs 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 208000037259 Amyloid Plaque Diseases 0.000 description 8
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
- 239000012156 elution solvent Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 7
- UZMQIGLCNLQYDJ-UHFFFAOYSA-N 4-[5-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-1,3-benzoxazol-2-yl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC(OCCOCCOCCF)=CC=C2O1 UZMQIGLCNLQYDJ-UHFFFAOYSA-N 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 7
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 7
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000000799 fluorescence microscopy Methods 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 238000000376 autoradiography Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- FRHRVQQUICVJDG-UHFFFAOYSA-M 1,3-dioxolan-2-ylmethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1OCCO1 FRHRVQQUICVJDG-UHFFFAOYSA-M 0.000 description 4
- FSMCQBBPBVEFNY-UHFFFAOYSA-N 2-[4-(methylamino)phenyl]-1,3-benzoxazol-5-ol Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC(O)=CC=C2O1 FSMCQBBPBVEFNY-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- GXBRZUVCGIEWSC-GGWOSOGESA-N CN(C1=CC=C(S1)/C=C/C=C/C=O)C Chemical compound CN(C1=CC=C(S1)/C=C/C=C/C=O)C GXBRZUVCGIEWSC-GGWOSOGESA-N 0.000 description 4
- JHIACQDTASDAAW-ONEGZZNKSA-N CN(C1=CC=C(S1)/C=C/C=O)C Chemical compound CN(C1=CC=C(S1)/C=C/C=O)C JHIACQDTASDAAW-ONEGZZNKSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 150000004646 arylidenes Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- KECMLGZOQMJIBM-UHFFFAOYSA-N 2-[2-(2-chloroethoxy)ethoxy]ethanol Chemical compound OCCOCCOCCCl KECMLGZOQMJIBM-UHFFFAOYSA-N 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- ZLQGITSKRNWIOT-UHFFFAOYSA-N 5-(dimethylamino)furan-2-carbaldehyde Chemical compound CN(C)C1=CC=C(C=O)O1 ZLQGITSKRNWIOT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 3
- SHLFEMNRNIJTQU-GGWOSOGESA-N CN(C1=CC=C(O1)/C=C/C=C/C=O)C Chemical compound CN(C1=CC=C(O1)/C=C/C=C/C=O)C SHLFEMNRNIJTQU-GGWOSOGESA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000005388 borosilicate glass Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- LSDKOPMEZMBWQB-UHFFFAOYSA-N 2-[5-[6-(dimethylamino)-1,3-benzothiazol-2-yl]penta-2,4-dienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C2N=C(C=CC=CC=C(C#N)C#N)SC2=C1 LSDKOPMEZMBWQB-UHFFFAOYSA-N 0.000 description 2
- KMYDAFODXPWYTQ-UHFFFAOYSA-N 2-[7-[6-(dimethylamino)-1,3-benzothiazol-2-yl]hepta-2,4,6-trienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C2N=C(C=CC=CC=CC=C(C#N)C#N)SC2=C1 KMYDAFODXPWYTQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101100328189 Bacillus anthracis clpP2 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZVIDMSBTYRSMAR-UHFFFAOYSA-N N-Methyl-4-aminobenzoate Chemical compound CNC1=CC=C(C(O)=O)C=C1 ZVIDMSBTYRSMAR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- KYIDWERKVBGXBC-UHFFFAOYSA-N n,n-dimethyl-1,3-benzothiazol-6-amine Chemical compound CN(C)C1=CC=C2N=CSC2=C1 KYIDWERKVBGXBC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PIZYNSXKSIBMJE-OKWWDJPNSA-N (2E,4E,6E)-7-[4-(dimethylamino)phenyl]hepta-2,4,6-trienal Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=C\C=O)C=C1 PIZYNSXKSIBMJE-OKWWDJPNSA-N 0.000 description 1
- JYHAOJGBXVCDOC-GGWOSOGESA-N (2e,4e)-5-[4-(dimethylamino)phenyl]penta-2,4-dienal Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=O)C=C1 JYHAOJGBXVCDOC-GGWOSOGESA-N 0.000 description 1
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 1
- GJOFJIQRZWCVLD-BDWKERMESA-N 2-[(2E,4E)-5-[5-(dimethylamino)furan-2-yl]penta-2,4-dienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=C(C#N)C#N)O1 GJOFJIQRZWCVLD-BDWKERMESA-N 0.000 description 1
- CRTLOGGIESVJPF-BDWKERMESA-N 2-[(2E,4E)-5-[5-(dimethylamino)thiophen-2-yl]penta-2,4-dienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=C(C#N)C#N)S1 CRTLOGGIESVJPF-BDWKERMESA-N 0.000 description 1
- DHMCTLHAIRCCEC-GJOOXVBWSA-N 2-[(2E,4E,6E)-7-[5-(dimethylamino)thiophen-2-yl]hepta-2,4,6-trienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=C\C=C(C#N)C#N)S1 DHMCTLHAIRCCEC-GJOOXVBWSA-N 0.000 description 1
- BFARWNGBCHXSTB-GGWOSOGESA-N 2-[(2e,4e)-5-[4-(dimethylamino)phenyl]penta-2,4-dienylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=C(C#N)C#N)C=C1 BFARWNGBCHXSTB-GGWOSOGESA-N 0.000 description 1
- NQRJRPLDEQLQLE-UHFFFAOYSA-N 2-[2-[2-[[2-[4-(dimethylamino)phenyl]-1,3-benzoxazol-5-yl]oxy]ethoxy]ethoxy]ethanol Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC(OCCOCCOCCO)=CC=C2O1 NQRJRPLDEQLQLE-UHFFFAOYSA-N 0.000 description 1
- XEZKBVOLHKUIAK-UHFFFAOYSA-N 2-[2-[2-[[2-[4-(methylamino)phenyl]-1,3-benzoxazol-5-yl]oxy]ethoxy]ethoxy]ethanol Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC(OCCOCCOCCO)=CC=C2O1 XEZKBVOLHKUIAK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BWOJSVZRONTERQ-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-1,3-benzoxazol-5-ol Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC(O)=CC=C2O1 BWOJSVZRONTERQ-UHFFFAOYSA-N 0.000 description 1
- IYNONQVNLZATDK-UHFFFAOYSA-N 2-[[4-(dimethylamino)phenyl]methylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(C=C(C#N)C#N)C=C1 IYNONQVNLZATDK-UHFFFAOYSA-N 0.000 description 1
- GMONWYMESVXLJO-UHFFFAOYSA-N 2-[[5-(dimethylamino)thiophen-2-yl]methylidene]propanedinitrile Chemical compound CN(C)C1=CC=C(C=C(C#N)C#N)S1 GMONWYMESVXLJO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TUADYTFWZPZZTP-UHFFFAOYSA-N 2-amino-4-methoxyphenol Chemical compound COC1=CC=C(O)C(N)=C1 TUADYTFWZPZZTP-UHFFFAOYSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- BIZFSZYEKCGRJJ-UHFFFAOYSA-N 4-(5-methoxy-1,3-benzoxazol-2-yl)-N,N-dimethylaniline Chemical compound N=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N(C)C)C=C1 BIZFSZYEKCGRJJ-UHFFFAOYSA-N 0.000 description 1
- AQMLIIVVTCGVJV-UHFFFAOYSA-N 4-(5-methoxy-1,3-benzoxazol-2-yl)-N-methylaniline Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC(OC)=CC=C2O1 AQMLIIVVTCGVJV-UHFFFAOYSA-N 0.000 description 1
- IXWYRQOHGLPBMP-UHFFFAOYSA-N 4-[5-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-1,3-benzoxazol-2-yl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC(OCCOCCOCCF)=CC=C2O1 IXWYRQOHGLPBMP-UHFFFAOYSA-N 0.000 description 1
- RRQFJMCAGDOEPI-UHFFFAOYSA-N 5-(dimethylamino)thiophene-2-carbaldehyde Chemical compound CN(C)C1=CC=C(C=O)S1 RRQFJMCAGDOEPI-UHFFFAOYSA-N 0.000 description 1
- WJTFHWXMITZNHS-UHFFFAOYSA-N 5-bromofuran-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)O1 WJTFHWXMITZNHS-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- QLUFBCVWKTWKBF-UHFFFAOYSA-N 6-nitro-1,3-benzothiazole Chemical compound [O-][N+](=O)C1=CC=C2N=CSC2=C1 QLUFBCVWKTWKBF-UHFFFAOYSA-N 0.000 description 1
- ALOSDHUIZWQDLC-UHFFFAOYSA-N 7-[6-(dimethylamino)-1,3-benzothiazol-2-yl]hepta-2,4,6-trienal Chemical compound CN(C)C1=CC=C2N=C(C=CC=CC=CC=O)SC2=C1 ALOSDHUIZWQDLC-UHFFFAOYSA-N 0.000 description 1
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 description 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CISMEWQMZBOLBR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N(C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)OCCOCCOCCC)C Chemical compound C(C)(C)(C)OC(=O)N(C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)OCCOCCOCCC)C CISMEWQMZBOLBR-UHFFFAOYSA-N 0.000 description 1
- DWRSZGAZUAMNLN-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)N=C(S2)C=CC=O Chemical compound CN(C)C1=CC2=C(C=C1)N=C(S2)C=CC=O DWRSZGAZUAMNLN-UHFFFAOYSA-N 0.000 description 1
- SZLDPNWFLPNDSQ-OKWWDJPNSA-N CN(C)c1ccc(\C=C\C=C\C=C\C=C(C#N)C#N)cc1 Chemical compound CN(C)c1ccc(\C=C\C=C\C=C\C=C(C#N)C#N)cc1 SZLDPNWFLPNDSQ-OKWWDJPNSA-N 0.000 description 1
- LQVQQNFHTAOBDW-UHFFFAOYSA-N CN(C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)OCCOCCOCCC2=C(C=CC(=C2)C)S(=O)(=O)O)C Chemical compound CN(C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)OCCOCCOCCC2=C(C=CC(=C2)C)S(=O)(=O)O)C LQVQQNFHTAOBDW-UHFFFAOYSA-N 0.000 description 1
- IIHQTBVWGZRFOR-ONEGZZNKSA-N CN(C1=CC=C(O1)/C=C/C=O)C Chemical compound CN(C1=CC=C(O1)/C=C/C=O)C IIHQTBVWGZRFOR-ONEGZZNKSA-N 0.000 description 1
- CXQYWDDZQIIYIV-OKWWDJPNSA-N CN(C1=CC=C(S1)/C=C/C=C/C=C/C=O)C Chemical compound CN(C1=CC=C(S1)/C=C/C=C/C=C/C=O)C CXQYWDDZQIIYIV-OKWWDJPNSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- PPXGQLMPUIVFRE-UHFFFAOYSA-N penta-2,4-dienal Chemical compound C=CC=CC=O PPXGQLMPUIVFRE-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/10—The polymethine chain containing an even number of >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/14—Styryl dyes
Definitions
- the present invention relates to a near-infrared fluorescent compound and a benzoxazole derivative. These compounds can be used for diagnosis of conformational diseases.
- AD Alzheimer's disease
- Senile plaque is the most characteristic brain lesion of AD, and its main component is amyloid ⁇ protein (A ⁇ ) having a ⁇ sheet structure. Imaging of senile plaques from outside the body is thought to lead to the establishment of an effective diagnostic method for AD, but imaging requires an amyloid imaging probe that specifically binds to A ⁇ .
- Known amyloid imaging probes include radioactive probes used in PET and SPECT (Patent Document 1) and fluorescent probes using donor-acceptor type fluorescent molecules (Patent Document 2).
- a compound used as an amyloid imaging probe is required to have high binding specificity for A ⁇ , high blood-brain barrier permeability, and rapid disappearance from the brain. Furthermore, the compound used as a fluorescent probe is also required to emit near-infrared light excellent in biological penetration.
- the object of the present invention is to provide a novel compound having the above properties.
- the present inventor has found that a compound having a benzoxazole skeleton has high binding specificity for A ⁇ , high permeability of the blood brain barrier, and rapid disappearance from the brain.
- an aromatic ring compound having a dimethylamino group and a dicyanovinyl group emits near-infrared fluorescence, and completed the present invention.
- any one of R 1 and R 2 is an electron donating group, the other is an electron withdrawing group, X and Y are the same or different, and are a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom. And Z is an oxygen atom or a sulfur atom, and m represents an integer of 0 to 5.
- X and Y are the same or different, and are a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom.
- Z is an oxygen atom or a sulfur atom
- m represents an integer of 0 to 5.
- the electron donating group is a hydroxyl group, methoxy group, methyl group, amino group, methylamino group, dimethylamino group, methylaminophenyl group, or dimethylaminophenyl group
- the electron withdrawing group is a nitro group, a nitrovinyl group
- the compound or a pharmaceutically acceptable salt thereof according to (1) which is a cyano group, a dicyanovinyl group, a tricyanovinyl group, or a formyl group.
- R 3 represents a hydroxy group, a C 1-3 alkoxy group, a C 1-3 alkoxy group containing a radioactive carbon atom, a halogen atom, a radioactive halogen atom, a chelate moiety bonded to a radioactive metal, or — (CH 2 CH 2 O) i -A [wherein i represents an integer of 1 to 10, and A represents a chelate moiety bonded to a halogen atom, a radioactive halogen atom, or a radioactive metal.
- R 4 represents a hydroxy group, a methoxy group, — (CH 2 CH 2 O) j —OH [wherein j represents an integer of 1 to 10.
- the radioactive halogen atom is 18 F, 123 I, 124 I or 125 I.
- the compound or pharmaceutically acceptable salt thereof according to (3), wherein the chelate moiety bound to the radioactive metal is a chelate moiety that binds to 99m Tc or 68 Ga.
- a composition for diagnosing conformation disease comprising the compound according to any one of (1) to (5).
- the compound of the present invention has a high binding specificity for A ⁇ , it is useful for early and accurate diagnosis of conformational diseases such as AD.
- the synthesis route of the near-infrared fluorescent compound of Example 1. The fluorescence spectrum of the near-infrared fluorescent compound of Example 1. The upper curve was measured in the presence of A ⁇ , and the lower curve was measured in the absence of A ⁇ . The figure which shows the result of the saturation binding assay to the A (beta) 42 aggregate of the near-infrared fluorescent compound of Example 1.
- FIG. Fluorescent staining of a Tg model mouse brain tissue section using the near-infrared fluorescent compound of Example 1. Fluorescence imaging of Tg model mice using KR-5. Fluorescent staining of Tg model mouse brain tissue sections using KR-5.
- the synthesis route of the near-infrared fluorescent compound of Example 2 (hereinafter sometimes referred to as “DANIR”).
- Fluorescence spectra of near-infrared fluorescent compounds of Example 2 (A and B, DANIR-1; DC and D, DANIR-2; E and F, DANIR-3; G and H, DANIR-4; left, EX right, EM).
- a and B DANIR-1; DC and D, DANIR-2; E and F, DANIR-3; G and H, DANIR-4; left, EX right, EM).
- DANIR 2-4 Fluorescent staining of DANIR 2-4 on a section of brain tissue from AD human (93 years old,) female).
- DANIR-2 A, Tx-red
- DANIR-3 C, Cy5
- DANIR-4 (E, Cy5.5).
- A, C, E A ⁇ plaque
- B, D, F NFTs (neurofibrillary tangles).
- Reagents (a) dimethylamine, H 2 O; (b) malononitrile, pyridine, 2-propanol; (c) (1,3-dioxalan-2-ylmethyl) triphenylphosphonium bromide, NaH, 18-crown-6, THF. Fluorescent staining of brain sections of Tg2576 mice. A, C, E, G, I, and K are images stained with DTA-0, DTA-1, DFA-1, DTA-2, DFA-2, and DTA-3, respectively. B, D, F, H, J, and L are images obtained by staining adjacent sections of A, C, E, G, I, and K with thioflavin S, respectively.
- R 1 and R 2 in general formula (I) may be either one of an electron donating group and the other an electron withdrawing group, but R 1 is an electron In the donor group, R 2 is preferably an electron withdrawing group.
- R 1 in the general formula (I) may be in any position on the heterocyclic ring, but is preferably in the 6-position (position assuming that the heterocyclic ring is benzothiazole).
- the electron donating group in formula (I) is preferably a hydroxyl group, a methoxy group, a methyl group, an amino group, a methylamino group, a dimethylamino group, a methylaminophenyl group, or a dimethylaminophenyl group, and more preferably Is a dimethylamino group.
- the electron withdrawing group in the general formula (I) is preferably a nitro group, a nitrovinyl group, a cyano group, a dicyanovinyl group, a tricyanovinyl group, or a formyl group, and more preferably a dicyanovinyl group.
- X in the general formula (I) is preferably nitrogen.
- Y in the general formula (I) is preferably sulfur.
- M in the general formula (I) may be an integer of 0 to 5, and is preferably 1 or 2.
- m when m is 0, it means that R 2 is directly bonded to the heterocyclic ring.
- Typical compounds among the compounds represented by the general formula (I) are shown in the following table.
- “Me” represents a methyl group
- “Dicyano” represents a dicyanovinyl group
- “Tricyano” represents a tricyanovinyl group
- “6-” represents a 6-position (complex of general formula (I)). It represents that the ring is a group at the position (assuming that it is benzothiazole).
- preferred compounds include I-23 (KR-5), I-35 (KR-7), and I-47 (KR-9).
- the compound represented by the general formula (I) can be synthesized by bonding an electron donating group and an electron withdrawing group directly or via an unsaturated carbon chain to a heterocyclic compound such as benzothiazole.
- R 1 in the general formula (II) may be in any position on the benzene ring, but is preferably in the para position.
- the electron donating group in the general formula (II) is preferably a hydroxyl group, a methoxy group, a methyl group, an amino group, a methylamino group, a dimethylamino group, a methylaminophenyl group, or a dimethylaminophenyl group, and more preferably Is a dimethylamino group.
- the electron withdrawing group in the general formula (II) is preferably a nitro group, a nitrovinyl group, a cyano group, a dicyanovinyl group, a tricyanovinyl group, or a formyl group, and more preferably a dicyanovinyl group.
- M in the general formula (II) may be an integer of 0 to 5, but is preferably 2 or 3.
- m when m is 0, it means that R 2 is directly bonded to the benzene ring.
- Typical compounds among the compounds represented by the general formula (II) are shown in the following table.
- “Me” represents a methyl group
- “Dicyano” represents a dicyanovinyl group
- “Tricyano” represents a tricyanovinyl group
- “p-” represents a para-position group.
- preferred compounds include II-11 (DANIR-1), II-23 (DANIR-2), II-35 (DANIR-3), and II-47 (DANIR-4).
- the compound represented by the general formula (II) can be synthesized by bonding an electron donating group and an electron withdrawing group to a compound having a benzene ring directly or via an unsaturated carbon chain.
- C Compound represented by the general formula (III)
- the “C 1-3 alkoxy group” is, for example, a methoxy group, an ethoxy group, an n-propoxy group, or an isopropoxy group. .
- the “C 1-3 alkyl group” is, for example, a methyl group, an ethyl group, an n-propyl group, or an isopropyl group.
- halogen atom is, for example, F, Cl, Br, or I.
- the “radiohalogen atom” is, for example, 18 F, 131 I, 125 I, 123 I, 124 I, 77 Br, or 76 Br.
- the “radioactive carbon atom” is, for example, 11 C.
- the “radioactive metal” is, for example, 99m Tc, 62 Cu, 67 Ga, or 68 Ga. As these radioactive metals, 99m Tc and 68 Ga are suitable.
- a chelate moiety bonded to a radioactive metal is, for example, an N 2 S 2 type metal chelate moiety bonded to the radioactive metal.
- R 3 in the general formula (III) is preferably a radioactive halogen atom, and more preferably 18 F, 123 I, 124 I or 125 I.
- R 4 in the general formula (III) is preferably a group represented by —NRaRb, and more preferably a dimethylamino group or a methylamino group.
- N in the general formula (III) may be an integer of 0 to 5, but is preferably 1, 2, or 3.
- n when n is 0, it means that R 3 is directly bonded to the benzoxazole ring.
- i is preferably 1, 2, or 3.
- J in the formula: — (CH 2 CH 2 O) j —OH is preferably 1, 2, or 3.
- K in the formula: — (CH 2 CH 2 O) k —F is preferably 1, 2, or 3.
- preferred compounds include III-26 ([ 18 F] compound 7) and III-27 ([ 18 F] compound 15).
- the compound represented by the general formula (III) can be synthesized according to the method described in the examples or according to a method in which those methods are appropriately modified or modified with reference to the description.
- R 1 and R 2 (D) a compound represented by the general formula (IV) formula in (IV) is a one of an electron donating group, but the other may be an electron withdrawing group, R 1 is an electron In the donor group, R 2 is preferably an electron withdrawing group.
- R 1 in the general formula (IV) may be in any position on the heterocycle, but is preferably in the 5-position (position when the heterocycle is assumed to be thiophene).
- the electron donating group in the general formula (IV) is preferably a hydroxyl group, a methoxy group, a methyl group, an amino group, a methylamino group, a dimethylamino group, a methylaminophenyl group, or a dimethylaminophenyl group, and more preferably Is a dimethylamino group.
- the electron withdrawing group in the general formula (IV) is preferably a nitro group, a nitrovinyl group, a cyano group, a dicyanovinyl group, a tricyanovinyl group, or a formyl group, and more preferably a dicyanovinyl group.
- M in the general formula (IV) may be an integer of 0 to 5, and is preferably 1 or 2.
- m when m is 0, it means that R 2 is directly bonded to a thiophene ring or the like.
- Typical compounds among the compounds represented by the general formula (IV) are shown in the following table.
- “Me” represents a methyl group
- “Dicyano” represents a dicyanovinyl group
- “Tricyano” represents a tricyanovinyl group
- “5-” represents the 5-position (complex of general formula (IV)). It represents that the ring is a group at the position when it is assumed to be thiophene.
- preferred compounds are IV-23 (DTA-1), IV-35 (DTA-2), IV-47 (DTA-3), IV-71 (DFA-1), IV-83 (DFA -2).
- the compound represented by the general formula (IV) can be synthesized by bonding an electron donating group and an electron withdrawing group directly or via an unsaturated carbon chain to a compound having a thiophene ring or a furan ring.
- (E) Composition for diagnosing conformation disease The composition containing the compounds represented by the general formulas (I) to (IV) described above can be used for diagnosis of conformation disease.
- pharmaceutically acceptable salts can be used in place of the compounds represented by the general formulas (I) to (IV).
- examples of pharmaceutically acceptable salts include alkali metal salts (sodium salt, potassium salt, lithium salt), alkaline earth metal salts (calcium salt, magnesium salt), sulfate, hydrochloride, nitrate, phosphate, etc. it can.
- Conformation disease means a group of diseases caused by proteins that have become abnormal due to conformational transformation such as A ⁇ , tau protein, prion, etc.
- AD hereditary cerebral dysemia with Down syndrome and Dutch amyloidosis (hereditary) cerebral hemorrhage with amyloidosis-Dutch type: HCHWA-D), Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), and type 2 diabetes.
- diseases to be diagnosed include precursor symptoms of diseases that are generally not recognized as “diseases”. Examples of prodromal symptoms of such diseases include mild cognitive impairment (MCI) seen before the onset of AD.
- MCI mild cognitive impairment
- this composition is usually administered to a subject to be diagnosed or a laboratory animal, and then a brain image is taken and represented by the general formulas (I) to (IV) in the image. Based on the state (amount, distribution, etc.) of the compound to be produced.
- the method of administration of the composition is not particularly limited and can be appropriately determined according to the type of compound, the type of labeling substance, etc., but is usually intradermal, intraperitoneal, intravenous, arterial or spinal fluid injection or Administer by infusion.
- the dose of the composition is not particularly limited, and can be appropriately determined according to the type of compound, the type of labeling substance, etc.
- the compound represented by general formulas (I) to (IV) is 1 It is preferable to administer 10 ⁇ 10 to 10 ⁇ 3 mg per day, and more preferably 10 ⁇ 8 to 10 ⁇ 5 mg.
- this composition since this composition is usually administered by injection or infusion, it may contain components usually contained in injection solutions or infusion solutions.
- Such components include liquid carriers (for example, potassium phosphate buffer, physiological saline, Ringer's solution, distilled water, polyethylene glycol, vegetable oils, ethanol, glycerin, dimethyl sulfoxide, propylene glycol, etc.), antibacterial agents And local anesthetics (eg, procaine hydrochloride, dibucaine hydrochloride, etc.), buffer solutions (eg, Tris-HCl buffer solution, Hepes buffer solution, etc.), osmotic pressure regulators (eg, glucose, sorbitol, sodium chloride, etc.) .
- liquid carriers for example, potassium phosphate buffer, physiological saline, Ringer's solution, distilled water, polyethylene glycol, vegetable oils, ethanol, glycerin, dimethyl sulfoxide, propylene glycol, etc.
- All the compounds showed binding ability to A ⁇ aggregates in the order of nM, and the binding properties improved in the order of PP-BTA-1 ⁇ KR-5 ⁇ KR-9 ⁇ KR-7.
- the bound and free radioactivity was then separated by vacuum filtration through a borosilicate glass fiber filter (Whatman GF / B) using an M-24 cell harvester (Brandel, Gaithersburg, MD).
- the radioactivity of the filter containing bound 125 I ligand was measured with a ⁇ -counter (WALLAC / Wizard 1470, USA) with an efficiency of 70%. Under the assay conditions, the specific binding fraction accounted for 10% of the total radioactivity.
- DANIR-3 Brain fluorescence imaging of DANIR-3 in vivo in normal and Tg mice (FIGS. 14 and 15) 50 ⁇ L of DANIR-3 (0.4 mg / kg, 20% DMSO, 80% propylene glycol) was injected into normal C57-BL6 and Tg-2576 (20 months) mice in vivo. Fluorescent signals from the brain were recorded by the Xenogen's IVIS 200 Imaging station at various times after injection and the data analyzed by Living Image Software. The ROI was drawn around the brain area and a time intensity curve was drawn.
- Example 3 Benzoxazole Derivatives (1) General Review Unless otherwise indicated, all reagents were obtained commercially and used without further purification. Using a JEOL JNM-AL400 NMR spectrometer at 400 MHz, a 1 H-NMR spectrum was obtained in CDCl 3 solution using TMS as an internal standard. Chemical shifts are reported as ⁇ values relative to the internal standard TMS. Coupling constants are reported in Hertz. Multiplicity is defined by s (single line), d (double line), t (triple line), and m (multiple line). Mass spectra were obtained with Shimadzu GC MS-QP2010 Plus (APCI).
- [18 F] 7 and [18 F] 15 procedure [18 F] labeled fluoride is produced by 18 O (p, n) 18 F reaction by JSW TypeBC3015 cyclotron, 18 O enriched water The solution was passed through a Sep-Pak Light QMA cartridge (Waters). The cartridge was dried in a stream of air and the 18 F - activity was eluted with K 2 CO 3 solution (33 mM). Kryptofix 222 (6-8 mg) was dissolved in [ 18 F] fluoride aqueous solution. The solvent was removed at 120 ° C. under a nitrogen stream. The residue was azeotroped twice with 0.3 mL anhydrous acetonitrile at 120 ° C. under a stream of nitrogen.
- the bound and free radioactive fractions were then separated by vacuum filtration using a M-24 cell harvester (Brandel, Gaithersburg, MD) through a borosilicate glass fiber filter (Whatman GF / B). Radioactivity from the filter containing bound 125 I ligand was measured with a ⁇ -counter (WALLAC / Wizard 1470, USA) with 70% efficiency. Under the assay conditions, the specific binding fraction accounted for 10% of the total radioactivity.
- Sections were incubated with radiolabeled tracer (10 ⁇ Ci / 100 ⁇ L) for 1 hour at room temperature, then washed with 50% ethanol for 1 hour and rinsed with water for 1 minute. After drying, the labeled sections were exposed to a Fujifilm imaging plate overnight. In vitro autoradiographic images were obtained using the BAS5000 scanner system (Fuji Film). The presence and location of plaques in the sections were confirmed by fluorescent staining with thioflavin S or immunohistochemical staining with BC05 (Wako), a monoclonal A ⁇ 1-42 antibody.
- a ⁇ (1-42) aggregates PBS (pH 7.4) was used to prepare A ⁇ (1-42) at a concentration of 0.25 mg / mL.
- An A ⁇ (1-42) aggregate solution was prepared by incubating at 37 ° C. for 42 hours. The aggregate solution was stored at ⁇ 80 ° C. until used for experiments.
- DTA1-3 and DFA-1,2 had binding affinity for A ⁇ aggregates.
- DTA-0 showed no binding affinity for A ⁇ aggregates.
- the five compounds except DTA-0 selectively bound to amyloid plaques accumulated on model mouse brain slices. Moreover, when it stained with thioflavin S using the adjacent section
- a ⁇ imaging reagents for the purpose of AD diagnosis, development support for therapeutic agents targeting A ⁇ , and disease state determination using A ⁇ accumulation in AD patients as an index.
Abstract
L'objet de la présente invention concerne un composé émettant une lumière dans le proche infrarouge ayant la capacité de se lier très spécifiquement à l'Aβ, une perméabilité élevée à travers la barrière hémato-encéphalique, la capacité de disparaître rapidement du cerveau, et une bioperméabilité élevée. Un composé ayant un squelette benzoxazole et un composé aromatique contenant un groupe diméthylamino, un groupe dicyanovinyle, etc. sont également décrits. Dans la formule (I), soit R1 soit R2 est un groupe donneur d'électrons et l'autre est un groupe attracteur d'électrons; X et Y sont identiques ou différents et chacun représente un atome de carbone, un atome d'azote, un atome d'oxygène ou un atome de soufre; et m est un entier de 0 à 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011182148 | 2011-08-24 | ||
JP2011-182148 | 2011-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013027694A1 true WO2013027694A1 (fr) | 2013-02-28 |
Family
ID=47746434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/070978 WO2013027694A1 (fr) | 2011-08-24 | 2012-08-20 | Sondes pour l'imagerie moléculaire permettant de diagnostiquer une maladie de conformation |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2013027694A1 (fr) |
WO (1) | WO2013027694A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276296A (zh) * | 2017-12-13 | 2018-07-13 | 潍坊润中精细化工有限公司 | 一种氰化物解毒剂的合成方法 |
KR20210107294A (ko) * | 2020-02-24 | 2021-09-01 | 건국대학교 산학협력단 | 알부민 정량을 위한 근적외선 형광 센서 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531133A (ja) * | 2000-04-13 | 2003-10-21 | エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ | 細胞増殖を調節する新規化合物 |
JP2004506723A (ja) * | 2000-08-24 | 2004-03-04 | ユニバーシティー オブ ピッツバーグ | アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 |
WO2007041241A2 (fr) * | 2005-09-30 | 2007-04-12 | The Trustees Of Columbia University In The City Of New York | Compositions et procedes permettant la detection des interactions ligand-recepteur |
JP2008546804A (ja) * | 2005-06-24 | 2008-12-25 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 造影剤として用いるためのリガンドの放射性標識ペグ化 |
JP2009516649A (ja) * | 2005-10-31 | 2009-04-23 | メルク エンド カムパニー インコーポレーテッド | Cetp阻害薬 |
JP2010189359A (ja) * | 2009-02-20 | 2010-09-02 | Kyoto Univ | ベンゾチアゾール誘導体含有診断用組成物 |
-
2012
- 2012-08-20 WO PCT/JP2012/070978 patent/WO2013027694A1/fr active Application Filing
- 2012-08-20 JP JP2013530010A patent/JPWO2013027694A1/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531133A (ja) * | 2000-04-13 | 2003-10-21 | エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ | 細胞増殖を調節する新規化合物 |
JP2004506723A (ja) * | 2000-08-24 | 2004-03-04 | ユニバーシティー オブ ピッツバーグ | アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 |
JP2008546804A (ja) * | 2005-06-24 | 2008-12-25 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 造影剤として用いるためのリガンドの放射性標識ペグ化 |
WO2007041241A2 (fr) * | 2005-09-30 | 2007-04-12 | The Trustees Of Columbia University In The City Of New York | Compositions et procedes permettant la detection des interactions ligand-recepteur |
JP2009516649A (ja) * | 2005-10-31 | 2009-04-23 | メルク エンド カムパニー インコーポレーテッド | Cetp阻害薬 |
JP2010189359A (ja) * | 2009-02-20 | 2010-09-02 | Kyoto Univ | ベンゾチアゾール誘導体含有診断用組成物 |
Non-Patent Citations (5)
Title |
---|
FERRIGHI,L. ET AL.: "Density-functional-theory study of the electric-field-induced second harmonic generation (EFISHG) of push-pull phenylpolyenes in solution", CHEMICAL PHYSICS LETTERS, vol. 425, no. 4-6, 2006, pages 267 - 272, XP027876658, DOI: doi:10.1016/j.cplett.2006.04.112 * |
GRACZA,T. ET AL.: "New method of preparation of 5-(dimethylamino)-2-furylethylenes via furan vinamidinium salts", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 51, no. 4, 1986, pages 879 - 88 * |
HROBARIK,P. ET AL.: "Computational design of benzothiazole-derived push-pull dyes with high molecular quadratic hyperpolarizabilities", PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 6, no. 3, 2004, pages 495 - 502 * |
LAPORTE,S.L. ET AL.: "The application of malononitriles as microviscosity probes in pharmaceutical systems", PHARMACEUTICAL RESEARCH, vol. 12, no. 3, 1995, pages 380 - 6, XP002954839, DOI: doi:10.1023/A:1016252518401 * |
LEE,H.S. ET AL.: "Chemometric studies on brain-uptake of PET agents via VolSurf analysis", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 29, no. 1, 2008, pages 61 - 68 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276296A (zh) * | 2017-12-13 | 2018-07-13 | 潍坊润中精细化工有限公司 | 一种氰化物解毒剂的合成方法 |
CN108276296B (zh) * | 2017-12-13 | 2020-09-11 | 潍坊润中精细化工有限公司 | 一种氰化物解毒剂的合成方法 |
KR20210107294A (ko) * | 2020-02-24 | 2021-09-01 | 건국대학교 산학협력단 | 알부민 정량을 위한 근적외선 형광 센서 |
KR102302318B1 (ko) | 2020-02-24 | 2021-09-14 | 건국대학교 산학협력단 | 알부민 정량을 위한 근적외선 형광 센서 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2013027694A1 (ja) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017204357B2 (en) | Novel compound for imaging tau protein accumulated in the brain | |
JP6370361B2 (ja) | アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物 | |
EP2023919A2 (fr) | Composés et sondes amyloïdes de ceux-ci pour des utilisations thérapeutiques et en imagerie | |
EP2501696A2 (fr) | Agents pour l'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératrices, notamment la maladie d'alzheimer et des maladies apparentées | |
Cui et al. | Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of β-amyloid plaques in Alzheimer's disease | |
JPWO2007135890A1 (ja) | 新規アミロイド親和性化合物 | |
WO2015110263A1 (fr) | Composés de carbazole et de carboline destinés à être utilisés dans le diagnostic, le traitement, l'atténuation ou la prévention de troubles associés aux protéines amyloïdes et de type amyloïde | |
JPWO2006057323A1 (ja) | アミロイド関連疾患診断用組成物 | |
WO2007148755A1 (fr) | Nouveau composé presentant une affinité pour une substance amyloïde | |
JPWO2005016888A1 (ja) | アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤 | |
JPWO2009054496A1 (ja) | 新規アミロイド親和性化合物 | |
JP5180838B2 (ja) | 新規アミロイド親和性化合物 | |
JP5048655B2 (ja) | 新規アミロイド親和性化合物 | |
Fuchigami et al. | Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT | |
CA2500358A1 (fr) | Sondes pour maladies liees a l'accumulation d'amyloide, agents de coloration d'amyloide, medicaments pour traitement et la prophylaxie de maladies liees a l'accumulation d'amyloide, et sondes de diagnostique d'enchevetrement neurofibrillaire et agents de coloration en matiere d'enchevetrement neurofibrillaire | |
Cui et al. | Synthesis and evaluation of benzofuran-2-yl (phenyl) methanone derivatives as ligands for β-amyloid plaques | |
WO2013027694A1 (fr) | Sondes pour l'imagerie moléculaire permettant de diagnostiquer une maladie de conformation | |
AU2004221897A2 (en) | Benzothiazole derivative compounds, compositions and uses | |
JPWO2009057576A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
JPWO2008068974A1 (ja) | オーロン誘導体含有診断用組成物 | |
WO2010125907A1 (fr) | Composition de diagnostic d'une maladie post-transcriptionnelle | |
EP3661930A1 (fr) | Ligands sélectifs pour agrégats tau | |
WO2023098622A1 (fr) | LIGAND DE LIAISON À PETITE MOLÉCULE D'AGRÉGAT D'α-SYNUCLÉINE, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS | |
WO2023104148A1 (fr) | SONDE À PETITES MOLÉCULES SE LIANT À L'AGRÉGAT D'α-SYNUCLÉINE ET APPLICATION DE CELLE-CI | |
JP2010189359A (ja) | ベンゾチアゾール誘導体含有診断用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12825580 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013530010 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12825580 Country of ref document: EP Kind code of ref document: A1 |